Incidence and prevalence of NMOSD in Australia and New Zealand
- 26 May 2017
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 88 (8), 632-638
- https://doi.org/10.1136/jnnp-2016-314839
Abstract
Objectives We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture–recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results NMOSD was confirmed in 81/170 (48%) cases referred. Capture–recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.Keywords
Funding Information
- Multiple Sclerosis Research Australia
- Griffith Health Institute, Griffith University
- National Health Service National Commissioning Group for Neuromyelitis Optica
- National Institute for Health Research Oxford Biomedical Research Centre
- Brain Foundation
- Gold Coast Hospital Foundation
This publication has 34 references indexed in Scilit:
- Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million PeoplePLOS ONE, 2013
- Molecular Pathogenesis of Neuromyelitis OpticaInternational Journal of Molecular Sciences, 2012
- Serologic diagnosis of NMONeurology, 2012
- The prevalence of neuromyelitis optica in South East WalesEuropean Journal of Neurology, 2011
- Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypesJournal of Neurology, Neurosurgery & Psychiatry, 2011
- A population-based study of neuromyelitis optica in CaucasiansNeurology, 2011
- MS prevalence in New Zealand, an ethnically and latitudinally diverse countryMultiple Sclerosis Journal, 2010
- AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevanceNature Reviews Neurology, 2010
- Neuromyelitis optica in FranceNeurology, 2010
- Neuromyelitis optica: a distinct demyelinating disease of the central nervous systemActa Neurologica Scandinavica, 2008